Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F7 | P08709 | 1/20 | 0.48 |
| ▸ | F3 | P13726 | 1/20 | 0.48 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.46 |
| ▸ | PYGL | P06737 | 1/20 | 0.41 |
| ▸ | CDK4 | P11802 | 2/20 | 0.41 |
| ▸ | CCND1 | P24385 | 2/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | NHERF1 | O14745 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14218479 | 0.85 | NR4A2 (0.50) | NR4A2 | |
| SCHEMBL3456794 | 0.82 | AVPR1A (0.52) | — | |
| SCHEMBL14218514 | 0.82 | NR4A2 (0.45) | NR4A2CDK4CCND1 | |
| SCHEMBL14218452 | 0.82 | CNR2 (0.44) | HDAC1HDAC6 | |
| SCHEMBL14218512 | 0.80 | HTR3E (0.35) | — | |
| SCHEMBL14218513 | 0.79 | HPGD (0.45) | HDAC1HDAC6 | |
| SCHEMBL14218586 | 0.79 | TUBB1 (0.50) | NR4A2CDK4CCND1 | |
| SCHEMBL14218551 | 0.78 | MEN1 (0.45) | HDAC1HDAC6 | |
| SCHEMBL14218550 | 0.75 | CNR2 (0.45) | HDAC1 | |
| SCHEMBL14218480 | 0.72 | NR3C1 (0.40) | NR4A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080108598-A1 | Pharmaceutical use of substituted amides | NOVO NORDISK A/S (DK) | 2008-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108598-A1 | Pharmaceutical use of substituted amides | HSD11B1, HSD3B1, HSD11B2 | F7 4274/4885F3 3399/4885NR4A2 1414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.